Plans Accelerated for Human Trials of Tooth Regeneration
Futurism • • health
Key Points:
- Japanese pharmaceutical company Toregem Biopharma has developed a new method to inhibit a gene that suppresses tooth growth, aiming to enable the growth of new living teeth as replacements for damaged ones.
- The company has raised approximately $5.3 million to accelerate clinical development, including plans for a Phase 2 clinical trial in Japan, though no specific timeline has been provided.
- Previous studies demonstrated success in mice by using a neutralizing antibody to suppress the USAG-1 protein, restoring teeth in genetically deficient animals, with early human safety trials underway but results pending.
- Experts caution that the treatment may only be effective in children due to the presence of dental epithelial cells necessary for tooth development, and there are concerns about controlling tooth growth to avoid unwanted effects.
- Despite uncertainties, the potential to regrow natural teeth represents a significant advancement in dentistry, warranting continued research and clinical investigation.